Manufacturer / China / Initial technical review
Ginseng, Ganoderma and Polygonum candidates for cosmetic-formulation review. We manufacture in our own R&D platform and consider particle-load customization against an agreed specification and QC protocol.
Ecyto is the overseas business of Shaanxi Yisai'er Biotechnology Co., Ltd. Initial review does not establish finished-formula compatibility or authorize sample dispatch.
Three candidates
Select a serum, lotion or cream project. Source identity alone does not establish efficacy.
Plant-derived / GS
Panax ginseng
Fresh main root. Freeze-dried preparation with trehalose, mannitol and sucrose.
Historical sample result, not a commercial acceptance limit or efficacy claim.
View Ginseng briefDiscuss Ginseng evaluationFungal-derived / GL
Ganoderma lucidum
Fruiting body. Freeze-dried preparation with trehalose, mannitol and sucrose.
Historical sample result, not a commercial acceptance limit or efficacy claim.
View Ganoderma briefDiscuss Ganoderma evaluationPlant-derived / PC
Polygonum cuspidatum
Fresh main root. Freeze-dried preparation with trehalose, mannitol and sucrose.
Historical sample result, not a commercial acceptance limit or efficacy claim.
View Polygonum briefDiscuss Polygonum evaluationReference evidence
Candidate-specific technical-evaluation sheets and reference particle/protein records are available. Particle reports use NanoCoulter resistive pulse sensing (RPS / Coulter principle), not NTA. RPS does not by itself establish EV purity or biological activity; BCA reports protein, not EV solid mass.
Each brief identifies its reference lot. Particle values use the company-confirmed 5 mL analytical reconstitution. Historical samples are not future-batch specifications.
R&D proposes cool-down addition below 40 C with gentle mixing and an initial pH 5-8 screen. These are starting proposals, not validated compatibility limits. Follow reviewed instructions for the actual sample.
Photographs reproduced from the existing company initial-review pack. They are not process validation or a product-performance claim.
Finished-product development example
In an existing multi-ingredient serum design, a freeze-dried portion and a liquid base are stored separately and mixed before use.
This illustrates a finished-product format, not a validated reconstitution time, compatibility result or stability claim for the B2B raw material. Performance must be assessed in the actual formula.
Documentation and naming
Candidate briefs, corresponding technical-evaluation TDS, available reference reports and a proposed evaluation workflow.
Reviewed safety documentation, actual-batch QA release, storage/transport instructions and destination import arrangements. Commercial MOQ, fees, price and lead time are confirmed separately.
INCI naming applications have been submitted. Results are expected in late November 2026, subject to review; neither the date nor the outcome is guaranteed. Naming does not establish ingredient safety or destination-market authorization.
ISO 9001:2015 certificate 041026Q00515R101 states validity through 1 June 2029, subject to surveillance. Its technical-R&D scope is not ISO 22716, a product approval or a sterile-product release claim. These materials are not proposed for human administration, injection or therapeutic use.
Initial review
Start with one candidate and one formula type. No order or confidential formula is needed to request existing information.
A first paid raw-material evaluation has no minimum vial count. Production-order terms are separate. Any dispatch is subject to actual-batch documentation, QA release, transport and destination import review.
Runji YangGeneral Manager, Overseas Businessrunji.yang@ecytobiotech.com+86 180 9246 1963